MEOBF Stock Chart & Stats
$1.60
$0.00(0.00%)
At close: 4:00 PM EST
$1.60
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.97 - $2.59
Previous CloseN/A
Volume20.00
Average Volume (3M)69.00
Market Cap
$2.34B
Enterprise Value$3.52K
Total Cash (Recent Filing)$129.57M
Total Debt (Recent Filing)$135.14M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding1,296,862,800
10 Day Avg. Volume100
30 Day Avg. Volume69
Financial Highlights & Ratios
PEG Ratio-27.18
Price to Book (P/B)2.09
Price to Sales (P/S)72.48
P/FCF Ratio-24.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.68Price Target Upside67.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$140.40M
Bulls Say, Bears Say
Bulls Say
Successful Ryoncil Commercial LaunchMaterial early commercial traction shows durable product-market fit: rapid center onboarding, strong H1 sales and full-year guidance imply the therapy is being adopted by treating centers and payers. That adoption supports sustainable revenue growth as the company scales pediatric penetration and executes label expansion.
Very High Gross Margins On Product SalesA 93% gross margin indicates the product has significant margin leverage and allows gross-profit funding of commercial and development activities. High product-level profitability improves long-term margin sustainability even if SG&A/R&D rises and supports attractive economics as sales scale across more centers and indications.
Strong Cash Position And Financing FlexibilityA sizable cash balance plus a large nondilutive facility provides runway to fund commercialization, pivotal trials and BLA activities without immediate equity dilution. This balance sheet flexibility reduces short-term financing risk and supports execution of multi-year clinical and commercial plans.
Bears Say
Revenue Concentration In One ProductDependence on a single product for nearly all revenues concentrates commercial, reimbursement and clinical risk. Any adverse payer decisions, safety signals, production disruption, or competitive entries could materially affect company cash flow and ability to fund pipeline programs over the next several quarters.
Sharply Higher R&D And SG&A SpendingSubstantially higher development and commercial costs elevate cash burn and pressure operating cash flow. Even with growing product revenue, elevated R&D and SG&A require persistent execution to convert investments into additional approvals or durable margins, making cash runway and cost discipline a medium-term risk.
Manufacturing/CMC And Regulatory Execution RiskPending validation of manufacturing, potency assays and labeling discussions creates execution risk ahead of BLAs. Delays or additional data/CMC requirements can push approvals or increase costs, threatening timely market expansion and the company's ability to translate trial results into broader, durable commercial uptake.
Mesoblast Limited News
MEOBF FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest stock price was $0.96 and its highest was $2.59 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is $2.34B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is Sep 02, 2026 which is in 47 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -$0.031 earnings per share for the quarter, missing the consensus estimate of -$0.007 by -$0.024.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is >-0.01.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,296,862,800 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -$0.031 in its last earnings report, missing expectations of -$0.007. Following the earnings report the stock price went down -2.516%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in MEOBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.68 (67.61% Upside)
$2.68 (67.61% Upside)
Blogger Sentiment
Bullish
MEOBF Sentiment 96%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.82%
12-Months-Change
Fundamentals
Return on Equity
-14.02%
Trailing 12-Months
Asset Growth
19.74%
Trailing 12-Months
Company Description
Mesoblast Limited
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.
MEOBF Stock 12 Month Forecast
Average Price Target
$2.68
▲(67.61% Upside)
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Ownership Overview
23.12% Insiders
2.36% Mutual Funds
0.01% Other Institutional Investors
71.94% Public Companies and
Individual Investors